Pathogenesis of Non-alcoholic Steatohepatitis: Human Data

McCullough, 2005, The epidemiology and risk factors of NASH, 23 Ludwig, 1980, Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hither to un-named disease, Mayo Clin Proc, 55, 434 Browning, 2004, Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity, Hepatology, 40, 1387, 10.1002/hep.20466 Falck-Ytter, 2001, Clinical features and natural history of nonalcoholic steatosis syndrome, Semin Liver Dis, 21, 17, 10.1055/s-2001-12926 Matteoni, 1999, Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity, Gastroenterology, 116, 1413, 10.1016/S0016-5085(99)70506-8 McCullough, 2005, Pathophysiology of non-alcoholic hepatitis, J Clin Gastroenterol, 39, 1 Chitturi, 2004, Non-alcoholic steatohepatitis in the Asia-pacific region: future shock?, J Gastroenterol Hepatol, 19, 368, 10.1111/j.1440-1746.2003.03252.x Chitturi, 2005, NAFLD/NASH is not just a “Western” problem: some perspectives on NAFLD/NASH from the East, 219 Bacon, 1994, Non-alcoholic steatohepatitis: an expanded clinical entity, Gastroenterology, 107, 1103, 10.1016/0016-5085(94)90235-6 Powell, 1990, The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years, Hepatology, 11, 74, 10.1002/hep.1840110114 Lee, 1989, Non-alcoholic steatohepatitis: a study of 49 patients, Hum Pathol, 20, 594, 10.1016/0046-8177(89)90249-9 Hui, 2003, Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C, Hepatology, 38, 420, 10.1053/jhep.2003.50320 Rratziu, 2002, Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis, Hepatology, 35, 1485, 10.1053/jhep.2002.33324 Caldwell, 1999, Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease, Hepatology, 32, 689 Caldwell, 2002, Subacute liver failure in obese women, Am J Gastroenterol, 97, 2058, 10.1111/j.1572-0241.2002.05922.x Bugianesi, 2002, Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular cancer, Gastroenterology, 123, 134, 10.1053/gast.2002.34168 Ong, 2001, Cryptogenic cirrhosis and post-transplantation nonalcoholic fatty liver disease, Liver Transpl, 7, 707, 10.1053/jlts.2001.24644 Harrison, 2003, The natural history of nonalcoholic fatty liver disease: a clinical histopathological study, Am J Gastroenterol, 98, 2024, 10.1111/j.1572-0241.2003.07659.x Fassio, 2004, Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies, Hepatology, 40, 820 Adams, 2005, The natural history of nonalcoholic fatty liver disease: a population-based study, Gastroenterology, 129, 113, 10.1053/j.gastro.2005.04.014 Hui, 2005, Histological progression of non-alcoholic fatty liver disease in Chinese patients, Aliment Pharmacol Ther, 21, 407, 10.1111/j.1365-2036.2005.02334.x Teli, 1995, The natural history of nonalcoholic fatty liver. A follow-up study, Hepatology, 22, 1714, 10.1002/hep.1840220616 Dam-Larsen, 2004, Long term prognosis of fatty liver disease and death, Gut, 53, 750, 10.1136/gut.2003.019984 Flegal, 2002, Prevalence and trends in obesity among US adults 1999–2000, JAMA, 288, 1723, 10.1001/jama.288.14.1723 Mokdad, 2001, The continuing epidemics of obesity and diabetes in the United States, JAMA, 286, 1195, 10.1001/jama.286.10.1195 Strauss, 2001, Epidemic increase in childhood overweight, 1986-1998, JAMA, 286, 2845, 10.1001/jama.286.22.2845 Hill, 2003, Obesity and the environment: where do we go from here?, Science, 299, 853, 10.1126/science.1079857 Blair, 2002, The public health problem of increasing prevalence rates of obesity and what should be done about it, Mayo Clin Proc, 77, 109, 10.4065/77.2.109 Kimm, 2002, Decline in physical activity in black and white girls during adolescence, N Engl J Med, 347, 709, 10.1056/NEJMoa003277 Kyle, 2004, Sedentarism affects body fat mass index and fat free mass index in adults aged 18-98 years, Nutrition, 20, 255, 10.1016/j.nut.2003.11.019 VanDamm, 2002, Dietary patterns and risk for type 2 diabetes mellitus in US men, Ann Intern Med, 136, 201, 10.7326/0003-4819-136-3-200202050-00008 Seidell, 2000, Obesity, insulin resistance and diabetes. A world wide epidemic, Br J Nutr, 83, 55 Kalhan, 2001, Altered lipid profile, leptin, insulin and anthropometry in offspring of South Asian immigrants, Metabolism, 50, 1197, 10.1053/meta.2001.26704 Weiss, 1984, A new world syndrome of metabolic diseases with a genetic and evolutionary basis, Yearb Phys Anthropol, 27, 153, 10.1002/ajpa.1330270508 Musso, 2003, Dietary habits and their relation to insulin resistance and post-prandial lipemia in nonalcoholic steatohepatitis, Hepatology, 37, 904, 10.1053/jhep.2003.50132 Solga, 2004, Dietary composition and nonalcoholic fatty liver disease, Dig Dis Sci, 49, 1578, 10.1023/B:DDAS.0000043367.69470.b7 Palmer, 1990, Effect of weight reduction on hepatic abnormalities in overweight patients, Gastroenterology, 99, 1408, 10.1016/0016-5085(90)91169-7 Ueno, 1997, Therapeutic effects of restricted diet and exercise in obese patients with fatty liver, J Hepatol, 27, 103, 10.1016/S0168-8278(97)80287-5 Park, 1995, Effects of weight control on hepatic abnormalities in obese patients with fatty liver, J Korean Med Sci, 10, 414, 10.3346/jkms.1995.10.6.414 Dixon, 2004, Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss, Hepatology, 39, 1647, 10.1002/hep.20251 Wang, 2003, Is weight reduction an effective therapy for nonalcoholic fatty liver? A systemic review, Am J Med, 115, 554, 10.1016/S0002-9343(03)00449-2 Mattar, 2005, Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome, Ann Surg, 242, 610, 10.1097/01.sla.0000179652.07502.3f Kral, 2004, Morbid obesity, nonalcoholic fatty liver disease and weight loss surgery, Surgery, 135, 48, 10.1016/j.surg.2003.10.003 Silverman, 1995, Regression of hepatic steatosis in morbidly obese persons after gastric bypass, Am J Clin Pathol, 104, 23, 10.1093/ajcp/104.1.23 Barker, 2006, Non-alcoholic steatohepatitis: effect of Roux-en-Y gastric bypass surgery, Am J Gastroenterol, 101, 368, 10.1111/j.1572-0241.2006.00419.x Rajala, 2003, The adipocyte—at the crossroads of energy, homeostasis, inflammation and atherosclerosis, Endocrinology, 144, 3765, 10.1210/en.2003-0580 Ahima, 2000, Adipose tissue as an endocrine organ, Trends Endocrinol Metab, 11, 327, 10.1016/S1043-2760(00)00301-5 Tilg, 2003, Cytokines in alcoholic and nonalcoholic steatohepatitis, N Engl J Med, 43, 1467 Li, 2005, Cytokines and inflammatory recruitment in NASH: experimental and human studies, 123 Uygun, 2000, Serum leptin levels in patients with nonalcoholic steatohepatitis, Am J Gastroenterol, 95, 3584, 10.1111/j.1572-0241.2000.03297.x LeClercq, 2002, Leptin is essential for the hepatic fibrogenic response to chronic liver injury, J Hepatol, 37, 206, 10.1016/S0168-8278(02)00102-2 Chalasani, 2003, Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis?, Am J Gastroenterol, 98, 2771, 10.1111/j.1572-0241.2003.08767.x Yamakawa, 1995, Augmented production of tumor necrosis factor-α in obese mice, Clin Immunol Immunopathol, 75, 51, 10.1006/clin.1995.1052 Aihand, 2002, Angiotensinogen, adipocyte differentiation and fatty mass enlargement, Curr Opin Clin Nutr Metab Care, 5, 385, 10.1097/00075197-200207000-00006 Yokohama, 2004, Therapeutic efficacy of angiotensinogen II receptor antagonist in patients with nonalcoholic steatohepatitis, Hepatology, 40, 1222, 10.1002/hep.20420 Boden, 2002, FFA cause hepatic insulin resistance by inhibiting insulin suppression of glycogenolysis, Am J Physiol Endocrinol Metab, 283, E12, 10.1152/ajpendo.00429.2001 Bergman, 2000, Free fatty acids and the pathogenesis of type 2 diabetes mellitus, Trends Endocrinol Metab, 11, 351, 10.1016/S1043-2760(00)00323-4 Berg, 2001, The adipocyte secreted protein ACRP 30 enhances hepatic insulin action, Nat Med, 7, 947, 10.1038/90992 Pajvani, 2003, Adiponectin: systemic contributor to insulin sensitivity, Curr Diab Rep, 3, 207, 10.1007/s11892-003-0065-2 Spranger, 2003, Adiponectin and protection against type 2 diabetes mellitus, Lancet, 361, 226, 10.1016/S0140-6736(03)12255-6 Yamauchi, 2001, The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity, Nat Med, 7, 941, 10.1038/90984 Tomas, 2002, Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation, Proc Natl Acad Sci U S A, 99, 16300, 10.1073/pnas.222657499 Yamauchi, 2002, Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase, Nat Med, 8, 1288, 10.1038/nm788 Xu, 2003, The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice, J Clin Invest, 112, 91, 10.1172/JCI200317797 Hui, 2004, Beyond insulin resistance in NASSH: TNF-α or adiponectin?, Hepatology, 40, 46, 10.1002/hep.20280 Soodini, 2004, Adiponectin and leptin in relation to insulin sensitivity, Metab Syn Rel Dis, 2, 114, 10.1089/met.2004.2.114 Kaser, 2005, Adiponectin and its receptors in nonalcoholic steatohepatitis, Gut, 54, 117, 10.1136/gut.2003.037010 Wei, 2004, Effect of losartan, an angiotensin II antagonist, on hepatic fibrosis induced by CCl4 in rats, Dig Dis Sci, 49, 1589, 10.1023/B:DDAS.0000043369.88701.5b Crespo, 2001, Gene expression of tumor necrosis factor alpha and TNF receptors, p55 and p75 in nonalcoholic steatohepatitis patients, Hepatology, 34, 1158, 10.1053/jhep.2001.29628 Katsuki, 1998, Serum levels of tumor necrosis factor-α are increased in obese patients with non-insulin dependent diabetes mellitus, J Clin Endocrinol Metab, 83, 859, 10.1210/jc.83.3.859 Satapathy, 2004, Beneficial effects of tumor necrosis factor-α inhibition by pentoxifylline on clinical, biochemical and metabolic parameters of patients with nonalcoholic steatohepatitis, Am J Gastroenterol, 99, 1946, 10.1111/j.1572-0241.2004.40220.x Ueki, 2004, Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance and the metabolic syndrome of the mouse, Proc Natl Acad Sci U S A, 101, 10422, 10.1073/pnas.0402511101 Ueki, 2004, Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms, Mol Cell Biol, 24, 5434, 10.1128/MCB.24.12.5434-5446.2004 Samuel, 2004, Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease, J Biol Chem, 279, 32345, 10.1074/jbc.M313478200 Hotamisligil, 1996, IRS-1 mediated kinase activity in TNF-α and obesity induced insulin resistance, Science, 272, 665, 10.1126/science.271.5249.665 Shepherd, 1999, Glucose transporters and insulin action, N Engl J Med, 341, 248, 10.1056/NEJM199907223410406 Tafani, 2000, Cytochrome dependent activation of caspase 3 by tumor necrosis factor requires induction of the mitochondrial permeability transition, Am J Pathol, 156, 2111, 10.1016/S0002-9440(10)65082-1 Pastorini, 1996, Cytotoxicity of TNF depends on induction of the mitochondrial permeability transition, J Biochem, 271, 29792 Li, 2004, A small molecule Smac mimic potentiates trail and TNFα-mediated cell death, Science, 305, 1471, 10.1126/science.1098231 Feldstein, 2003, Hepatocyte apoptosis and FAS expression are prominent features of human nonalcoholic steatohepatitis, Gastroenterology, 125, 437, 10.1016/S0016-5085(03)00907-7 Combs, 2001, Endogenous glucose production is inhibited by the adipose-derived protein Acrp30, J Clin Invest, 108, 1875, 10.1172/JCI14120 Kamada, 2003, Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adiponectin, Gastroenterology, 125, 1796, 10.1053/j.gastro.2003.08.029 Arner, 1998, Not all fat is alike, Lancet, 351, 1301, 10.1016/S0140-6736(05)79052-8 Basu, 2004, Splanchnic cortisol production occurs in humans. Evidence for conversion of cortisone to cortisol via the 11-B hydroxysteroid dehydrogenase (11-B-HSD) type 1 pathway, Diabetes, 53, 2051, 10.2337/diabetes.53.8.2051 Gavrila, 2003, Serum adiponectin levels are inversely associated with overall and central fat distribution but are not directly regulated by acute fasting or leptin administration in humans: cross-sectional and interventional studies, J Clin Endocrinol Metab, 88, 4823, 10.1210/jc.2003-030214 Nielsen, 2004, Splanchnic lipolysis in human obesity, J Clin Invest, 113, 1582, 10.1172/JCI21047 Nguyen-Duy, 2003, Visceral fat and liver fat are independent predictors of metabolic risk factors in men, Am J Physiol Endocrinol Metab, 284, E1065, 10.1152/ajpendo.00442.2002 Carr, 2004, Intraabdominal fat is a major determinant of the national cholesterol education program adult treatment panel III criteria for the metabolic syndrome, Diabetes, 53, 2087, 10.2337/diabetes.53.8.2087 Havel, 2004, Update on adipocyte hormones: regulation of energy balance and carbohydrate/lipid metabolism, Diabetes, 53, S143, 10.2337/diabetes.53.2007.S143 Basu, 2001, Systemic and regional free fatty acid metabolism in type 2 diabetes, Am J Physiol Metab, 280, E1000 Donnelly, 2005, Sources of fatty acids stored in the liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease, J Clin Invest, 115, 1343, 10.1172/JCI23621 Marchesini, 1999, Association of nonalcoholic fatty liver disease with insulin resistance, Am J Med, 107, 450, 10.1016/S0002-9343(99)00271-5 St-Onge, 2004, Metabolic syndrome in normal weight Americans, Diabetes Care, 27, 2222, 10.2337/diacare.27.9.2222 Marchesini, 2002, NASH: from liver disease to metabolic disorders and back to clinical hepatology, Hepatology, 135, 497, 10.1053/jhep.2002.31551 Vikram, 2003, Non-obese (body mass index < 25 kg/m2) Asian Indians with normal waist circumference have high cardiovascular risk, Nutrition, 19, 503, 10.1016/S0899-9007(02)01083-3 Marchesini, 2001, Nonalcoholic fatty liver disease. A feature of the metabolic syndrome, Diabetes, 50, 1844, 10.2337/diabetes.50.8.1844 Sanyal, 2001, Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities, Gastroenterology, 120, 1183, 10.1053/gast.2001.23256 Ioannou, 2005, Is central obesity associated with cirrhosis-related death on hospitalization? A population-based study, Clin Gastro Hepatol, 3, 67, 10.1016/S1542-3565(04)00442-2 Klein, 2004, Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease, N Engl J Med, 350, 2549, 10.1056/NEJMoa033179 Marchesini, 2005, NASH as part of the metabolic (insulin resistance) syndrome, 55 Marchesini, 2003, Nonalcoholic fatty liver, steatohepatitis and the metabolic syndrome, Hepatology, 37, 917, 10.1053/jhep.2003.50161 2001, Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486 Marceau, 1999, Liver pathology and the metabolic syndrome X in severe obesity, J Clin Endocrinol Metab, 84, 1513, 10.1210/jc.84.5.1513 Pagano, 2002, Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association, Hepatology, 35, 367, 10.1053/jhep.2002.30690 Chitturi, 2002, NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome, Hepatology, 35, 373, 10.1053/jhep.2002.30692 Chalasani, 2003, Metabolic and anthropometric evaluation of insulin resistance in nondiabetic patients with nonalcoholic steatohepatitis, Am J Gastroenterol, 98, 1849, 10.1111/j.1572-0241.2003.07619.x Petersen, 2003, Mitochondrial dysfunction in the elderly: possible role in insulin resistance, Science, 300, 1140, 10.1126/science.1082889 Iossa, 2004, A possible link between skeletal muscle mitochondrial efficacy and age induced insulin resistance, Diabetes, 53, 2861, 10.2337/diabetes.53.11.2861 Saltiel, 2001, Insulin signaling and the regulation of glucose and lipid metabolism, Nature, 414, 799, 10.1038/414799a Samuel, 2005, Insulin resistance in NAFLD: potential mechanisms and therapies, 38 Virkamaki, 1999, Protein-interaction in insulin signaling and the molecular mechanisms of insulin resistance, J Clin Invest, 103, 931, 10.1172/JCI6609 Combettes-Souverain, 1998, Molecular basis on insulin action, Diabetes Metab, 24, 477 Synkiotis, 2001, Serine phosphorylation of insulin receptor substrates-1: a novel target for the reversal of insulin resistance, Mol Endocrinol, 15, 1864, 10.1210/me.15.11.1864 Kido, 2000, Tissue specific resistance in mice with mutations in insulin receptor. IRS-1 and IRS-2, J Clin Invest, 105, 199, 10.1172/JCI7917 Previs, 2000, Contrasting effects of IRS-1 versus IRS-2 gene disruption on carbohydrate and lipid metabolism, J Biol Chem, 275, 38990, 10.1074/jbc.M006490200 Das, 2001, Is obesity an inflammatory condition?, Nutrition, 17, 953, 10.1016/S0899-9007(01)00672-4 Arkan, 2005, IKK-B links inflammation to obesity induced insulin resistance, Nat Med, 11, 191, 10.1038/nm1185 Day, 2006, From fat to inflammation, Gastroenterology, 130, 207, 10.1053/j.gastro.2005.11.017 Promrat, 2004, A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis, Hepatology, 39, 188, 10.1002/hep.20012 Neuschwander-Tetri, 2003, Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone, Hepatology, 38, 1008, 10.1053/jhep.2003.50420 Sekiya, 2003, Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP-1 suppression, Hepatology, 38, 1529, 10.1016/j.hep.2003.09.028 Yuan, 2001, Reversal of obesity and diet induced insulin resistance with salicylates on targeted disruption of IKKB, Science, 293, 1673, 10.1126/science.1061620 Kahn, 2000, Obesity and insulin resistance, J Clin Invest, 106, 473, 10.1172/JCI10842 Morrison, 1999, Insights into the transcriptional control of adipocyte differentiation, J Cell Biochem, 32, 59, 10.1002/(SICI)1097-4644(1999)75:32+<59::AID-JCB8>3.0.CO;2-1 Wiggs, 2001, The role of small intestinal overgrowth, intestinal permeability, endotoxemia, and tumor necrosis factor-α in the pathogenesis of nonalcoholic steatohepatitis, Gut, 48, 206, 10.1136/gut.48.2.206 Nazim, 1989, Nonalcoholic steatohepatitis associated with small intestinal diverticulosis and bacterial overgrowth, Hepatogastroenterology, 36, 349 Riordan, 2002, Small intestinal bacterial overgrowth, intestinal permeability, and non-alcoholic steatohepatitis, Gut, 50, 136, 10.1136/gut.50.1.136-a Solga, 2003, Nonalcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics, J Hepatol, 38, 681, 10.1016/S0168-8278(03)00097-7 Neyrinck, 2002, Inhibition of Kupffer cell activity induces hepatic triglyceride synthesis in fasted rats, independent of lipopolysaccharide challenge, J Hepatol, 36, 466, 10.1016/S0168-8278(02)00009-0 Yang, 1997, Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis, Proc Natl Acad Sci U S A, 94, 2557, 10.1073/pnas.94.6.2557 Li, 2003, Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease, Hepatology, 37, 343, 10.1053/jhep.2003.50048 Diraison, 2003, Contribution of hepatic de novo lipogenesis and re-esterification of plasma nonesterified fatty acids to plasma triglyceride synthesis during nonalcoholic fatty liver disease, Diabetes Metab, 29, 478, 10.1016/S1262-3636(07)70061-7 Charlton, 2002, Apolipoprotein synthesis in nonalcoholic steatohepatitis, Hepatology, 35, 898, 10.1053/jhep.2002.32527 Miele, 2003, Hepatic mitochondrial-beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test, Am J Gastroenterol, 98, 2335, 10.1111/j.1572-0241.2003.07725.x Kim, 2001, Tissue specific overexpression of lipoprotein lipase cause tissue specific insulin resistance, Proc Natl Acad Sci U S A, 98, 7522, 10.1073/pnas.121164498 Kim, 2003, Primary of hepatic insulin resistance in the development of the metabolic syndrome induced by an isocaloric moderate fat diet in the dog, Diabetes, 52, 2453, 10.2337/diabetes.52.10.2453 Bugianesi, 2005, Insulin resistance in non-diabetic patients with nonalcoholic fatty liver disease—sites and mechanisms, Diabetologia, 48, 634, 10.1007/s00125-005-1682-x Tikkainen, 2004, Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance and gene expression in adipose tissue in patients with type 2 diabetes, Diabetes, 53, 2169, 10.2337/diabetes.53.8.2169 Day, 1998, Steatohepatitis: a tale of two “hits”?, Gastroenterology, 114, 842, 10.1016/S0016-5085(98)70599-2 Washington, 2000, Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver, Hum Pathol, 31, 822, 10.1053/hupa.2000.8440 Yang, 2000, Mitochondrial adaptations to obesity-related oxidant stress, Arch Biochem Biophys, 378, 259, 10.1006/abbi.2000.1829 Chavin, 1999, Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion, J Biol Chem, 2784, 5692, 10.1074/jbc.274.9.5692 Cortez-Pinto, 1999, Alterations in liver ATP homeostasis in human non-alcoholic steatohepatitis. A pilot study, JAMA, 282, 1659, 10.1001/jama.282.17.1659 Caldwell, 2004, Mitochondria in nonalcoholic fatty liver disease, Clin Liver Dis, 8, 595, 10.1016/j.cld.2004.04.009 Day, 1998, Hepatic steatosis: innocent bystander or guilty party?, Hepatology, 27, 1463, 10.1002/hep.510270601 Dong, 1998, Cytokine expression in hepatocytes: role of oxidative stress, J Interferon Cytokine Res, 18, 629, 10.1089/jir.1998.18.629 Chitturi, 2001, Etiopathogenesis of non-alcoholic steatohepatitis, Semin Liver Dis, 21, 27, 10.1055/s-2001-12927 Pessayre, 2001, Mitochondria in steatohepatitis, Sem in Liv Dis, 21, 57, 10.1055/s-2001-12929 Day, 2002, Pathogenesis of steatohepatitis, Best Pract Res Clin Gastroenterol, 16, 663, 10.1053/bega.2002.0333 Letteron, 1996, Acute and chronic steatosis lead to in vivo lipid peroxidation in mice, J Hepatol, 24, 200, 10.1016/S0168-8278(96)80030-4 MacDonald, 2001, Lipid peroxidation in hepatic steatosis in humans is associated with hepatic fibrosis and occurs predominately in acinar zone 3, J Gastroenterol Hepatol, 8, 993 Mazzanti, 1989, Hepatic lipid peroxidation and aldehyde dehydrogenase activity in alcoholic and nonalcoholic liver disease, Alcohol Alcohol, 24, 121, 10.1093/oxfordjournals.alcalc.a044875 Garcia-Monzon, 2000, Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity, J Hepatol, 33, 716, 10.1016/S0168-8278(00)80301-3 Sumida, 2003, Serum thioredoxin levels is a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease, J Hepatol, 38, 32, 10.1016/S0168-8278(02)00331-8 Seki, 2002, In situ detection of lipid peroxidation and oxidative DNA damage in nonalcoholic fatty liver disease, J Hepatol, 37, 56, 10.1016/S0168-8278(02)00073-9 Koruk, 2004, Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis, Ann Clin Lab Sci, 34, 57 Parola, 1993, Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen alpha 1 (I) gene expression in human liver fat-storing cells, Biochem Biophys Res Commun, 194, 1044, 10.1006/bbrc.1993.1927 Lee, 1995, Activation of hepatic stellate cells by TGF alpha and collagen type J is mediated by oxidative stress through c-myb expression, J Clin Invest, 96, 2461, 10.1172/JCI118304 Bedossa, 1994, Stimulation of collagen alpha 1 (I) gene expression is associated with lipid peroxidation in hepatocellular injury: a link to tissue fibrosis?, Hepatology, 19, 1262 Choi, 2005, Role of inflammation in nonalcoholic steatohepatitis, Curr Opin Gastroenterol, 21, 702, 10.1097/01.mog.0000182863.96421.47 Parola, 2001, Oxidative stress-related molecules and liver fibrosis, J Hepatol, 35, 297, 10.1016/S0168-8278(01)00142-8 Goldstein, 2005, Insulin action is facilitated by insulin-stimulated reactive oxygen species with multiple potential signaling targets, Diabetes, 54, 311, 10.2337/diabetes.54.2.311 Wanless, 1989, Subcapsular steatonecrosis in response to peritoneal insulin deliver: a clue to the pathogenesis of steatonecrosis in obesity, Mod Pathol, 2, 69 Khalili, 2003, Hepatic subcapsular steatosis in response to intraperitoneal insulin delivery: CT findings and prevalence, AJR Am J Roentgenol, 180, 1601, 10.2214/ajr.180.6.1801601 Li, 2004, Insulin in UW solution exacerbates hepatic ischemia/reperfusion injury by energy depletion through the IRS-2/SREBP-1c pathway, Liver Transpl, 10, 1172, 10.1002/lt.20240 Paradis, 2001, High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis, Hepatology, 74, 738, 10.1053/jhep.2001.28055 Younossi, 2004, Nonalcoholic fatty liver disease in patients with type 2 diabetes, Clin Gastroenterol Hepatol, 2, 262, 10.1016/S1542-3565(04)00014-X El-Serag, 2004, Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma, Gastroenterology, 126, 460, 10.1053/j.gastro.2003.10.065 Ozcan, 2004, Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes, Science, 306, 457, 10.1126/science.1103160 Muoio, 2004, Insulin resistance takes a trip through the ER, Science, 306, 425, 10.1126/science.1104680 George, 1998, Increased Hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis, Gastroenterology, 114, 311, 10.1016/S0016-5085(98)70482-2 Bonkovsky, 1999, Nonalcoholic steatohepatitis and iron increased prevalence of mutations of the HFE gene in nonalcoholic steatohepatitis, J Hepatol, 31, 421, 10.1016/S0168-8278(99)80032-4 Angulo, 1999, Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis, Hepatology, 30, 1356, 10.1002/hep.510300604 Younossi, 1999, Hepatic iron and nonalcoholic fatty liver disease, Hepatology, 30, 847, 10.1002/hep.510300407 Chitturi, 2002, HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity, Hepatology, 36, 142, 10.1053/jhep.2002.33892 Bugianesi, 2004, Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver, Hepatology, 39, 179, 10.1002/hep.20023 Fargion, 2001, Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis, Am J Gastroenterol, 96, 2448, 10.1111/j.1572-0241.2001.04052.x Fernandez Real, 1998, Serum ferritin as a component of the insulin resistance syndrome, Diabetes Care, 21, 62, 10.2337/diacare.21.1.62 Mendler, 1999, Insulin resistance-associated hepatic iron overload, Gastroenterology, 117, 1155, 10.1016/S0016-5085(99)70401-4 MacDonald, 1999, More clues to the relationship between hepatic iron and steatohepatitis: an association with insulin resistance?, Gastroenterology, 117, 1241, 10.1016/S0016-5085(99)70412-9 Dinneen, 1994, Liver iron stores in patients with non-insulin dependent diabetes mellitus, Mayo Clin Proc, 69, 13, 10.1016/S0025-6196(12)61605-X Riquelme, 2004, Histological resolution of steatohepatitis after iron depletion, Dig Dis Sci, 49, 1012, 10.1023/B:DDAS.0000034564.68307.39 Fernandez-Real, 2002, Blood letting in high-ferritin type 2 diabetes: effects on vascular reactivity, Diabetes Care, 25, 2249, 10.2337/diacare.25.12.2249 Eaton, 2002, Molecular bases of cellular iron toxicity, Free Radic Biol Med, 32, 833, 10.1016/S0891-5849(02)00772-4 LeMasters, 2004, Rusty notions of cell injury, J Hepatol, 40, 696, 10.1016/j.jhep.2004.02.015 Rauen, 2004, Iron induced mitochondrial permeability transition in cultured hepatocytes, J Hepatol, 40, 607, 10.1016/j.jhep.2003.12.021 Bulteau, 2004, Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity, Science, 305, 242, 10.1126/science.1098991 Lieber, 2004, CYP2E1 from ASH to NASH, Hepatol Res, 28, 1, 10.1016/j.hepres.2003.08.001 Leclerq, 2000, CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis, J Clin Invest, 105, 1067, 10.1172/JCI8814 George, 2003, Lipid peroxidation stellate cell activation and hepatic fibrogenesis in a rat model of chronic steatohepatitis, J Hepatol, 39, 756, 10.1016/S0168-8278(03)00376-3 Videla, 2004, Oxidation stress-related parameters in the liver of nonalcoholic fatty liver disease patients, Clin Sci, 106, 261, 10.1042/CS20030285 Loguercio, 2001, Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects, J Hepatol, 35, 568, 10.1016/S0168-8278(01)00192-1 Nehra, 2001, Nutritional and metabolic considerations in the etiology of non-alcoholic steatohepatitis, Dig Dis Sci, 46, 2347, 10.1023/A:1012338828418 Mavretis, 1983, Hepatic free fatty acids in alcoholic liver disease and obesity, Hepatology, 3, 226, 10.1002/hep.1840030215 Clarke, 2001, Nonalcoholic steatosis and steatohepatitis. I. Molecular mechanism for polyunsaturated fatty acid regulation of gene transcription, Am J Physiol Gastrointest Liver Physiol, 281, G865, 10.1152/ajpgi.2001.281.4.G865 Rao, 2001, Peroxisomal beta-oxidation and steatohepatitis, Semin Liver Dis, 21, 1067, 10.1055/s-2001-12928 Weltman, 1996, Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation, Gastroenterology, 116, 1645, 10.1016/S0016-5085(96)70028-8 Weltman, 1998, Hepatic cytochrome P4502E1 is increased in patients with nonalcoholic steatohepatitis, Hepatology, 27, 128, 10.1002/hep.510270121 Chalasani, 2003, Hepatic cytochrome P4502E1 activity in non-diabetic patients with nonalcoholic steatohepatitis, Hepatology, 37, 544, 10.1053/jhep.2003.50095 De la Maza, 2000, Changes in microsomal activity in alcoholism and obesity, Alcohol Clin Exp Res, 24, 605, 10.1111/j.1530-0277.2000.tb02031.x Emery, 2003, CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease, Hepatology, 38, 428, 10.1053/jhep.2003.50342 Ip, 2004, Administration of the potent PPAR alpha agonist, Wyeth 14,643 reverses nutritional fibrosis and steatohepatitis in mice, Hepatology, 39, 1286, 10.1002/hep.20170 Araya, 2004, Increase in long-chain polyunsaturated fatty acid n–6/n–3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease, Clin Sci, 106, 635, 10.1042/CS20030326 Caldwell, 1999, Mitochondrial abnormalities in non-alcoholic steatohepatitis, J Hepatol, 31, 430, 10.1016/S0168-8278(99)80033-6 Perez-Carreras, 2003, Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis, Hepatology, 38, 999, 10.1053/jhep.2003.50398 Nair, 2003, Hepatic ATP reserve and efficiency of replenishing comparison between obese and non-obese normal individuals, Am J Gastroenterol, 98, 466 Caraceni, 2004, Impairment of mitochondrial oxidative phosphorylation in rat fatty liver exposed to preservation reperfusion injury, J Hepatol, 41, 82, 10.1016/j.jhep.2004.03.022 Dianzani, 1956, The effects of some inhibitors of oxidative phosphorylation on the morphology and enzymatic activities of mitochondria, Biochem J, 61, 205, 10.1042/bj0620205 Charlton, 2004, Nonalcoholic fatty liver disease: a review of current understanding and future impact, Clin Gastroenter Hepatol, 2, 1048, 10.1016/S1542-3565(04)00440-9 Al-osaimi, 2005, Intermittent disconjugate gaze: a novel finding in nonalcoholic steatohepatitis and cryptogenic cirrhosis, Hepatology, 41, 943, 10.1002/hep.20675 Lanquin, 2001, Diabetic insulin secretion and the pancreatic beta cell mitochondrion, N Engl J Med, 345, 1772, 10.1056/NEJM200112133452412 Poli, 2000, Pathogenesis of liver fibrosis: the role of oxidative stress, Mol Aspects Med, 21, 49, 10.1016/S0098-2997(00)00004-2 Rashid, 1999, Mitochondrial protein that regulate apoptosis and necrosis are induced in mouse fatty liver, Hepatology, 29, 1131, 10.1002/hep.510290428 Ribeiro, 2004, Hepatocyte apoptosis, expression of death receptors, and activation of NF-kappaB in the liver of nonalcoholic and alcoholic steatohepatitis patients, Am J Gastroenterol, 99, 1708, 10.1111/j.1572-0241.2004.40009.x Canbay, 2004, Apoptosis: the nexus of liver injury and fibrosis, Hepatology, 39, 273, 10.1002/hep.20051 Li, 2004, Norepinephrine regulates hepatic innate immune system in leptin deficient mice with nonalcoholic steatohepatitis, Hepatology, 40, 434, 10.1002/hep.20320 Guebre-Xabien, 1999, Altered hepatic lymphocyte subpopulations in obesity related fatty livers, Hepatology, 31, 633, 10.1002/hep.510310313 Feldstein, 2004, Free fatty acids promote hepatic lipotoxicity by stimulating TNFα expression via a lysosomal pathway, Hepatology, 40, 185, 10.1002/hep.20283 Ron, 2002, Translational control in the endoplasmic response, J Clin Invest, 110, 1383, 10.1172/JCI0216784 Hidvegi, 2005, Accumulation of mutant α, ATZ in the ER activates caspaces 4 and 12, NF-KB, and BAP31 but not the unfolded protein response, J Biol Chem, 280, 39002, 10.1074/jbc.M508652200 Sahai, 2004, Upregulation of osteopontin expression is involved in the development of nonalcoholic steatohepatitis in a dietary murine model, Am J Physiol Gastrointest Liver Physiol, 287, 264, 10.1152/ajpgi.00002.2004 Maeda, 2002, Diet induced insulin resistance in mice lacking adiponectin/ACRP 30, Nat Med, 8, 731, 10.1038/nm724 Feldstein, 2005, Apoptosis in alcoholic and nonalcoholic steatohepatitis, Front Biosci, 10, 3093, 10.2741/1765 Ramalho, 2006, Apoptosis and Bcl-2 expression in the livers of patients with steatohepatitis, Eur J Gastroenterol Hepatol, 18, 21, 10.1097/00042737-200601000-00005 Vendeniale, 2001, Mitochondrial oxidative injury and energy metabolism alteration in rat fatty liver: effect of the nutritional status, Hepatology, 33, 808, 10.1053/jhep.2001.23060 Abdelmalek, 2001, Betaine, a promising new agent for patients with non-alcoholic steatohepatitis. Results of a pilot study, Am J Gastroenterol, 96, 2711, 10.1111/j.1572-0241.2001.04129.x Mato, 1997, S-adenosylmethionine synthesis molecular mechanisms and clinical implications, Pharmacol Ther, 73, 265, 10.1016/S0163-7258(96)00197-0 McClain, 2002, S-Adenosylmethionine, cytokines, and liver disease, Alcohol, 27, 185, 10.1016/S0741-8329(02)00224-0 Duce, 1988, S-adenosyl-L-methionine synthetase and phospholipid methyltransferase are inhibited in human cirrhosis, Hepatology, 8, 65, 10.1002/hep.1840080113 Lu, 2001, Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation, Proc Natl Acad Sci U S A, 98, 5560, 10.1073/pnas.091016398 Mato, 1999, S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial, J Hepatol, 30, 1081, 10.1016/S0168-8278(99)80263-3 Lieber, 1999, Role of S-adenosyl-L-methionine in the treatment of liver disease, J Hepatol, 30, 1115, 10.1016/S0168-8278(99)80274-8 Li, 2006, The ratio of phosphatidycholine to phosphatidylethondione influence membrane integrity and steatohepatitis, Cell Metab, 3, 1, 10.1016/j.cmet.2006.03.007 Willner, 2001, Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency and severity of disease, Am J Gastroenterol, 96, 2957, 10.1111/j.1572-0241.2001.04667.x Struben, 2000, Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds, Am J Med, 108, 9, 10.1016/S0002-9343(99)00315-0 Sreekumar, 2003, Hepatic gene expression in histologically progressive non-alcoholic steatohepatitis, Hepatology, 38, 244, 10.1053/jhep.2003.50290 Younossi, 2005, A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease, Hepatology, 42, 665, 10.1002/hep.20838 Day, 2004, The potential role of genes in non-alcoholic fatty liver disease, Clin Liver Dis, 8, 673, 10.1016/j.cld.2004.04.001